Francis Collins says pharmaceutical companies should help bridge the gap between basic science and applications with old drug compounds.
The Scientist
Most Recent
Large molecules are more likely to make it to market these days than small molecules, according to new reports.
The FDA may require weight-loss drugs to undergo clinical trials to see if they pose a risk of heart attack.
Once a promising cancer treatment, the failure of PARP inhibitors in the clinic may be due to flawed preclinical studies.
Two new cancer cell line databases bursting with genomic and drug profiling data may help researchers identify drug targets.
Check out the latest crop of high-resolution structures and how they inform biological function.
A new bill recently debated in the US Congress seeks to streamline the approval process for drugs.
Over the past 15 years, new laws and regulations in the United States and the European Union have expanded to require the inclusion of pediatric patients in clinical drug trials. Before these laws were enacted, the US Food and Drug Administration (F
Two key pieces of legislation, enacted to spur drugmakers into testing pharmaceutical products in children, are up for reauthorization in the US Congress this October. Have they done their jobs?
A lot changes in a child’s body over the course of development, and not all changes occur linearly: gene expression can fluctuate, and organs can perform different functions on the way to their final purpose in the body. Here are some of the key deve
Follow The Scientist
Advertisement
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
